Virax Biolabs (VRAX) announced that it has signed a Purchase Order with Cosmos Health (COSM) to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. Pursuant to their previously signed distribution agreement dated September 2022, Cosmos will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the ViraxClear branded test kits across Europe on a non-exclusive basis.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRAX:
